FILE PHOTO: An Aspen Pharmacare logo is seen at outside company offices in Woodmead

South Africa's Aspen strikes distribution deal with U.S. drugmaker Mylan

JOHANNESBURG (Reuters) - Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.

The arrangement by Aspen Global Incorporated and its Australian subsidiaries includes an option for Mylan to buy the portfolio for approximately 188 million Australian dollars ($136 million), the company said in a statement.

Aspen said the deal was part of efforts to allow "enhanced operational focus" and reduce complexity, which also included it ending several third party licenses in Australia.

Separately, Aspen said it expects the sale of its infant formula business which it announced in September to French company Lactalis for 12.9 billion rand ($907 million) to take place by the first quarter of 2019.

Proceeds from the disposal will be used to reduce debt and it has engaged with its creditors to negotiate a conditional and temporary adjustment to its leverage ratio covenant as of the end of December, Aspen said.

This will allow for an increase in the covenant limit, should the transaction not be completed by Dec. 31.

($1 = 14.2184 rand)

($1 = 1.3837 Australian dollars)

(Reporting by Patricia Aruo; Editing by Alexander Smith)

First Published: 2018-12-14 09:57:35
Updated 2018-12-14 12:10:10

© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.